New York-based pharmaceutical giant Bristol-Myers Squibb has reportedly signed a deal worth $438 million with Reckitt Benckiser, a personal health products company based in the UK. According to reports, the deal will last for three years an includes an agreement to a $44 million option fee, giving Reckitt the option of buying Bristol-Myers brands at the end of the three years. The contract gives Bristol-Myers control over Reckitt manufacturing and, in turn, allows Reckitt to sell Bristol-Myers medicines throughout Latin America, especially Mexico and Brazil. Mexico and Brazil antitrust authorities may review the deal, however.
Featured News
Nigeria Antitrust Regulator Probes Uber’s Abrupt Exit
Sep 6, 2026 by
CPI
Verisign, ICANN Face Antitrust Lawsuit Over .Com Domain Pricing
Sep 6, 2026 by
CPI
US Justice Department Expands Beef-Pricing Probe to Grocery Chains
Sep 6, 2026 by
CPI
EU Lawmakers Press Brussels to Keep Breakup Option Open in Google Ad-Tech Case
Sep 6, 2026 by
CPI
AI Copyright Fight Expands as Regional Newspapers Target OpenAI, Microsoft
Sep 6, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – State Attorneys General
Aug 27, 2026 by
CPI
CPI Talks… with Jonathan Skrmetti, Attorney General of Tennessee
Aug 27, 2026 by
Jonathan Skrmetti
What the Live Nation Jury Instructions Tell Us About California’s Unfair Competition Law
Aug 27, 2026 by
Henry Hauser, Brent Nakamura, Ashley Kaplan, Brian Wang & Cari Jeffries
From Backroom Deals to Public Scrutiny: The Tunney Act’s Past, Present, and Future
Aug 27, 2026 by
Christina M. Black & Ashley A. Locke
Understanding the Fragility of Economic Concentration Through the Principles of Ecology
Aug 27, 2026 by
Alexandra Spring